Taurine ef ux occurs in association with cell swelling in both hyposmotic and isosmotic conditions and during cell shrinkage in apoptotic death. Release occurs through a leak pathway, is largely Ca 21 -independent and is sensitive to Cl channel blockers. Taurine ef ux elicited by hyposmolarity is reduced or suppressed by tyrosine kinase blockers and increased by tyrosine phosphatase inhibitors. The speci c kinases involved are still unknown and may be different in the various cell types. Non-receptor and scr-related protein kinases have been identi ed in some cells as elements that directly phosphorylate the taurine ef ux pathway. Possible tyrosine kinase targets are the phosphinositide kinase (PI3K), which if inhibited, prevents the osmosensitive taurine ef ux in brain cells, or the small GTP-binding proteins associated with remodeling of the cytoskeleton. The similar effects of tyrosine kinase modulators on volumeactivated taurine uxes and Cl currents are suggestive of either a shared translocation pathway or a common step in the signaling network. The effects of tyrosine kinases on taurine ef ux activated in isosmotic swelling and in the release associated with apoptosis are essentially unexplored.
Introduction
Taurine is released from diverse brain tissue preparations in response to a variety of stimuli, one of the most conspicuous being the reduction in external osmolarity. 1 Taurine release is activated by cell membrane depolarization and in conditions of ischemia, hypoxia, hyperammonemia and subsequent to generation of oxygen free radicals and membrane lipid peroxidation. [2] [3] [4] [5] Another stimulus consistently increasing taurine release from brain preparations is the activation of excitatory amino acid receptors by agonists such as glutamate, kainate, NMDA and quinolinic acid. Nitric oxide has been reported to increase taurine ef ux from cultured neurons and brain slices, an effect that could be either direct or through modulation of NMDA receptors. 2 It is so far unclear whether the release of taurine in all these different conditions is triggered by a common factor, or whether in each case the release operates through different avenues. A possibility is that taurine release is primarily a cell response to swelling. The bases to consider this possibility are, rst, that all these conditions involve a certain degree of swelling and second, that swelling consistently evokes taurine ef ux. Taurine is particularly suited for this osmolyte role, due to its metabolic inactivity and its high concentration as a free solute in the cytosol. 6 Taurine ef ux is evoked by hyposmotic and isosmotic cell swelling Swelling of brain cells may occur in hyposmotic or isosmotic conditions. The rst condition is the consequence of hyponatremia of various origins. 7 Isosmotic cell swelling, also referred as cytotoxic edema, occurs in association with ischemia, epilepsies, hepatic encephalopathy, hyperammonemia, head trauma and hypoglycemia. [8] [9] [10] [11] Swelling results from changes in ion distribution by dysfunction of ion transport mechanisms or by disruption of the membrane barrier subsequent to attack by free radical and lipoperoxidation, leading to ionic imbalance and overload, with the consequent water accumulation. [8] [9] [10] [11] In all cases, brain cell edema represents a situation of high risk, since the restriction to tissue expansion imposed by the rigid cranium, commonly leads to compression of small vessels generating episodes of ischemia, excitotoxicity and neuronal death.
Experimental paradigms in vitro and in vivo have been designed to simulate the conditions leading to brain cell edema in vivo. The most commonly used model for hyponatremia is to expose cells or tissue to a hyposmotic medium made by decreasing the concentration of NaCl. Under these conditions, cells initially swell and then undergo an active process of volume recovery accomplished by the extrusion of intracellular osmolytes. Hyposmolarity elicits taurine ef ux in essentially all cell types, including brain cells and also in brain tissue preparations. 1, 12, 13 In vivo, taurine ef ux from brain superfused with hyposmotic medium has been also consistently observed, and the increase of taurine in the extracellular space mirrors the decrease in intracellular levels. 14, 15, 16 The magnitude of taurine ef ux is proportional to the reduction in osmolarity, its time course roughly parallels that of the volume recovery and blockade of taurine ef ux or taurine de ciency impairs cell volume regulation. 1 In models of chronic hyponatremia in vivo, a continuous and progressive decrease in brain taurine levels is observed, to an extent that the intracellular pool is essentially depleted. 17 These results underlie the importance of taurine in the maintenance of normal brain water content, preventing the sequels of injury due to cell edema.
There is general agreement that osmosensitive taurine ef ux occurs through a leak pathway, with no contribution of the Na 1 -dependent carriers. 18 In most cell types taurine ef ux is sensitive to Cl 2 channel blockers, such as 5-nitro-(3-phenyl-propylamino) benzoic acid (NPPB), tamoxifen, and to the anion exchanger blockers ni umic acid, 4,4 1 -diisothiocyanatostil loene-2, 2 1 -discultonic acid (DIDS) and pyridoxal phosphate. [19] [20] [21] These features have raised the proposal of a common pathway (a Cl 2 channel-like molecule), for the osmosensitive transport of Cl 2 , taurine, and other organic osmolytes. 19 This common pathway hypothesis is not yet conclusive 21 and awaits the molecular identity of the volume-sensitive Cl 2 channel as well as more insight into the molecular nature of the taurine pathway itself.
While cell volume regulation after swelling evoked by hyposmolarity has been extensively investigated, it is still unclear whether such regulation occurs in cytotoxic edema and to what extent organic osmolytes may participate in the volume correction, or at least contribute to reduce the magnitude of swelling. Taurine release occurs consistently under conditions of cytotoxic edema 2 and its release is sensitive to Cl 2 channel blockers, suggesting a similarity with the mechanism of release in hyposmotic conditions. [22] [23] [24] However, it should be emphasized that even when cell swelling occurs by different mechanisms in each pathology, in most of them Cl 2 in ux is a causal factor. Therefore, the inhibitory action of Cl 2 channel blockers may be exerted on the Cl 2 in ux pathways, thus preventing swelling and consequently, the primary cause of taurine release.
Tyrosine kinases are involved in the hyposmolarity-evoked release of taurine
Most studies aiming to understand the in uence of tyrosine kinase-activated pathways during volume correction after hyposmotic swelling have been focussed on the volume-activated Cl 2 channel, 25 while similar investigations for taurine ef ux are still scarce. As mentioned before, the one pathway hypothesis for Cl 2 and taurine is not yet conclusive and therefore, results about signaling mechanisms modulating volume-activated Cl 2 channels should not be directly extrapolated to the osmosensitive taurine ef ux. Similarly, transduction steps leading to activation of taurine ef ux should not be naturally assumed to be the same for other organic osmolytes, nor even for other amino acids. This may be particularly true for tyrosine kinases as will be later discussed.
Evidence in support of the involvement of tyrosine kinases in the osmosensitive taurine ef ux relies on the effect of several tyrosine kinase blockers reducing the ef ux of taurine, while correspondingly, agents which inhibit tyrosine kinase phosphatases and prolong tyrosine phosphorylation, potentiate taurine release.
The general tyrosine kinase blockers tyrphostins, inhibit taurine release evoked by swelling in cultured cerebellar granule neurons and astrocytes, 26, 27 in the supraoptic nucleus 28 and in hippocampal slices 29 (Table  1) . Ortho-vanadate potentiates taurine ef ux in cerebellar granule neurons and astrocytes and in the supraoptic nucleus whereas it has no effect on taurine ef ux in hippocampal slices. These differences, also found in other cells (see below) may be due either to the involvement of tyrosine phosphatases with different sensitivities to the blocker or to differences in the permeability of ortho-vanadate in the various preparations.
Tyrosine kinase blockers also reduce the hyposmolarity-elicited taurine ef ux in non brain cells (Table 2 ). In skate blood erythrocytes, tyrphostins reduce hyposmolarity-induced taurine release 30 and in HeLa cells, genistein decreases and ortho-vanadate potentiates taurine ef ux. Also genistein reduces taurine ef ux in trout erythrocytes, but in the latter cells, the release is either unaffected or reduced by ortho-vanadate. 32 In a Langendorff heart preparation, taurine ef ux is reduced by genistein and lavendustin A. 33 Remarkably, this is the only study in vivo, addressing the in uence of tyrosine kinases on the mechanism of taurine release in hyposmotic conditions.
While taurine ef ux stimulated by hyposmolarity is clearly affected by tyrosine kinase blockers, other amino acids (GABA and glutamate) which are also released from brain cells by the hyposmotic stimulus, are insensitive to tyrosine kinase blockers, suggesting a lack of in uence of these kinases. 29 A similar insensitivity to Cl 2 channel blockers, in contrast to taurine, suggests a different pathway for the osmosensitive release of these amino acids. 29 In most cell types, the speci c kinases involved in the osmosensitive taurine ef ux have not yet been identi ed
The consistent effect of tyrosine kinase blockers reducing taurine ef ux in hyposmotic conditions, point to these enzymes as part of the osmotransduction signaling, connecting the change in cell volume and the activation of the taurine ef ux pathway. So far, though, in most cells the speci c kinases involved and the sites of their action remain to be identi ed. The most consistent work on the involvement of tyrosine kinases in hyposmolarity-activated taurine release has been carried out by Goldstein and coworkers, in a series of studies in the skate nucleated erythrocytes. The hyposmolarityinduced release of taurine in these cells appears to occur through the band 3 anion exchange protein. 34 Taurine release is reduced by tyrphostin A23, although it is insensitive to other tyrphostins and to genistein. 30 Hyposmosis leads to band 3 phosphorylation by the tyrosine kinases p76syk and p56lyn 30 and p72syk directly phosphorylates the cytoplasmic domain of the band 3 protein with a time course parallel to that of the swelling-activated taurine ef ux. 30 Accordingly, the p72syk inhibitor piceatannol blocks, at about the same concentration, both taurine ef ux and p72syk-dependent band 3 phosphorylation. 30 Moreover, the phosphatase blocker pervanadate similarly potentiates taurine ef ux and the activity of p72syk phosphorylation. 30 In this same preparation, various experimental paradigms were used to produce cell swelling with differences in the intracellular ionic strength, as this parameter seems to regulate the set point for taurine ef ux activation by cell swelling. 35, 36 The effect of intracellular strength reduction on the activity of the two tyrosine kinases involved in the band 3 phosphorylation and taurine ef ux was examined, and results are suggestive Tyrosine kinases and taurine release ½ 105 of some sensitivity of p72syk and p56lyn to the change in intracellular ionic strength. 37 In this respect, in the supraoptic nucleus, the magnitude of the effect of tyrosine kinase and phosphatase blockers is dependent on the external osmolarity, suggesting that tyrosine kinases modulate the sensitivity to hyposmolarity rather than the ef ux pathway activation. 28 The src-related tyrosine kinase p56lck is found to be a key signaling element for osmosensitive Cl 2 currents in lymphocytes, as shown by its activation upon swelling, suppression of osmosensitive currents in p56lck-de cient cells by genetic knockout and its restitution after retransfection of the kinase. 38 The involvement of this kinase on taurine ef ux has not yet been examined.
Apart from these studies in blood cells, the tyrosine kinases involved in taurine ef ux, and in that of other osmolytes as well, have not been identi ed. This is further complicated because tyrosine kinases are steps in the signaling cascades of numerous cell responses, many of which are activated by processes occurring in association with swelling and volume regulation, such as cell adhesion and retraction, reorganization of the cytoskeleton and gating of stretch-activated channels. Besides, swelling is a stressful condition for the cells, also activating signals associated with stress responses. Therefore, even the identi cation of the kinases activated by hyposmolarity ( Figure 1 ) may not be suf cient to ascribe them to the activation or operation of osmolyte extrusion pathways, including those for taurine. Examples of this situation are the phosphorylation by hyposmotic swelling of the mitogen-activated protein (MAP) kinases extracellular signal-related kinase-1/2 (ERK1/ERK2) observed in various cell types. 25, 39 This reaction mediates the swelling-induced transcription of early expression genes, 40 the volume-sensitive channels in astrocytes 41 and taurocholate excretion in hepatocytes; 39 but in most cell types and brain preparations such as cerebellar granule neurons, hippocampal slices, supraoptic nucleus, intestinal 407 cells and skate erythrocytes, even when MAP kinases are activated by hyposmolarity, preventing this reaction has no effect on osmolyte uxes, including Cl-and taurine. 25, 26, 28, 29, 42 An attractive hypothesis recently considered is that the integrin receptor could play a role in the sensing of cell volume changes by detecting membrane expansion or unfolding of membrane invaginations. 43 Integrin activation, possibly by receptor clustering, could initiate a signaling cascade via focal adhesion kinase (FAK), which is known to be activated by hyposmolarity. FAK, in turn, connects with a variety of signaling proteins such as src-related protein kinases, PI3K and small GTP-binding proteins associated with remodeling of the cytoskeleton. All these proteins have been found to be activated by hyposmolarity in different cells and many of them are related to taurine (or Cl 2 ) corrective uxes. Besides the already discussed link of taurine release with src-related kinases and other non receptor kinases in blood cells, other elements of this signaling cascade
Figure 1
Interactions between some membrane associated receptors and signaling cascades involving tyrosine kinases and tyrosine kinase-activated kinases. Enzymes in shaded circles are those activated by hyposmolarity. Receptors may be activated by adhesion reactions or by clustering due to membrane cytoskeleton reorganization as a consequence of swelling. TKR: tyrosine kinase receptors, GPCR: G protein coupled receptors, FAK: focal adhesion kinase, PI3K: phoshoinositide 3-kinase, SAPKS: stress-activated kinases, ERK1/2: extracellular regulated kinases 1 and 2, MEK: MAPK/ERK-kinase, GEFs: guanine exchange factors, GAPs: GTPase-activating proteins, srck: src-related kinases, Rhok: Rho-kinase. involved in osmolyte uxes include the small GTPase p21Rho, 44, 45 and particularly the phosphoinositide kinase PI3K. This enzyme, which is a key element in signaling networks connecting with integrins, FAK, srcrelated kinases and tyrosine kinase membrane receptors, appears to have a relevant role in the mechanisms of taurine release. In cerebellar granule neurons, astrocytes and hippocampal slices, hyposmolarity activates PI3K, and this reaction is blocked by wortmannin ( Figure  2A) . 26, 29 This agent is also a potent blocker of hyposmotic taurine release in these preparations ( Figure 2B ), suggesting a direct link of PI3K and the activation or/and operation of the taurine ef ux pathway. Wortmannin also blocks anion uxes activated by hyposmolarity in various cell types. 44, 47, 48 The similar effect of tyrphostins and wortmannin on taurine ef ux illustrated in Figure 2 is suggestive of PI3K as a main target of tyrosine kinase reactions in osmotransduction.
Tyrosine kinase receptors such as integrin, associated with many of those signaling elements may also have an in uence on osmolyte release, as suggested by a study on myoblasts, in which taurine ef ux is activated by thrombin and hyposmolarity, with similar characteristics. 46 The idea of integrin or other membrane receptors acting as a very early and basic mechanism of the signaling osmotransduction cascade, might also explain the many common effects of tyrosine kinases on Cl 2 and taurine uxes, and possibly on other organic osmolytes as well.
Are tyrosine kinases involved in the mechanism of taurine release in isosmotic conditions?
As previously mentioned, taurine ef ux is elicited in isosmotic conditions by a variety of stimuli, most of them having in common some extent of cell swelling due to intracellular ion redistribution. The mechanisms of taurine release in these conditions are still poorly de ned and may or may not be similar to those activated by hyposmotic swelling. The in uence of tyrosine kinases on taurine release is essentially unknown. Only two reports document the inhibitory effect of genistein and lavendustin on taurine release evoked by ischemiareperfusion in brain and heart. 49, 50 It should be noticed that, similar to hyposmolarity, or even more, ischemia evokes a large number of reactions and cell responses, many of them involving tyrosine kinase phosphorylations, thus making it dif cult to identify among those activated by the ischemic condition, which are directly related to the mechanism of taurine release.
Taurine release and apoptosis
Cell shrinkage is one of the hallmarks of apoptosis, though the mechanisms leading to this remarkable reduction in cell volume are still poorly understood. Moderate increases in external osmolarity inhibit apoptosis, suggesting an active role of cell volume as part of the signals leading to cell death. 51 Increasing external osmolarity may prevent the loss of osmotic solutes, and cell shrinkage, which may be a determinant in the initiation of the apoptotic events. Taurine appears to be one of those osmolytes. In Jurkat T lymphocytes, apoptosis induced by stimulation of the CD95 receptor, evokes a release of taurine. 52 An apoptosis-associated taurine release has been also found in cerebellar granule neurons. 53 At variance with the osmosensitive release of taurine, the apoptosis-related taurine ef ux is insensitive to Cl 2 channel blockers. 52, 53 The in uence of tyrosine kinases is essentially unknown, with only one report in Jurkat cells showing that src-related kinases are not involved, since neither herbimycin A, vanadate nor p56lck de ciency in uenced taurine release. 54 
Conclusions
The release of taurine associated with cell volume regulation is well established in conditions of hyposmolarity and tyrosine kinases likely play a critical role in the mechanisms of this release. The present knowledge, however, is still fragmentary, with studies carried out in different cell types or tissue preparations, different blockers and different experimental approaches, which makes it dif cult to identify the speci c tyrosine kinases involved in each cell type. As for the release of taurine in isosmotic conditions, the in uence of tyrosine kinases is essentially unexplored, as is that of the apoptosis-associated taurine ef ux. This is an interesting avenue for future research, which may give important clues about the similarities and dissimilarities of taurine release evoked by different stimuli.
